Clinical Trial Update: A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for a KN026-based combination therapy in HER2-positive gastric cancer (Phase 2/Phase 3), with recruitment not yet started.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• KN026

Snippet

Sponsor: Shanghai JMT-Bio Inc. | Conditions: HER2-positive Gastric Cancer | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING